omapro addressable market size, page-8

If Omapro is never commercialised then, sure, Chemgenex's current valuation won't be realised. But I thought we were debating the size and value of the market assuming successful commercialisation.

Assuming commercialisation, the European rights (subject to a royalty to Chemgenex) are worth $140 million, at least to Hospira.